65,437 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 14 — -31.24; -31.33; -19.24 milligram/deciliter (mg/dL)
Kaposi's Sarcoma
Primary: Localization — 5 participants
Blood Pressure · Anxiety
Primary: Incidence of Hypotension — 15; 5 participants
Asthma
Primary: Severe Exacerbations — 30.9; 23.6; 34; 36.5 Percentage subjects severe exacerbations
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks After End of Treatment — 0; 7.1; 20.8 percentage of participants — p=0.003
Premature Ejaculation
Primary: Mean Intravaginal Ejaculatory Latency Time (IELT): Change From Baseline to During 3 Month Double Blind-treatment — 4.607; 1.505 ratio — p=<0.0001
Crohn's Disease
Primary: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year — 1; 11 participants — p=.0005
Bone Loss · Hypotensive · Lower Limb Fluid Pooling
Primary: Bone Density of Proximal Femur — -0.133; -.675; 1.3 percent change in bone density
Chronic Hepatitis C
Primary: Percentage of Participants With Rapid Virologic Response (RVR) — 40.0; 41.7 percentage of participants
Epilepsy · Tuberous Sclerosis Complex
Primary: Reduction in Seizure Frequency — 60 percentage
Osteoarthritis · Rheumatoid Arthritis · Lower Back Pain
Primary: Efficacy According to BS-11 Pain Score Reduction — 2.7 units on a scale
Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Maximum Tolerated Dose (Phase I) — 0; 0; 0; 3 participants
Malignant Glioma · Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) at 6 Months — 0.29; 0.23 Months — p=0.26
Syncope · Recurrent Symptomatic Atrial Fibrillation
Primary: Success of Wireless Transmissions — 73.1 percentage of successful transmissions
Anorexia Nervosa
Primary: Serotonin Receptor 1A Binding Potential In Regions of Interest (ROI) Accounting for Binding Potential in a Region Without Serotonin 1A Receptors — 5.97; 5.89; 6.66; 6.91…